Next steps in asthma care

This module will explore issues such as the underuse of inhaled corticosteroids (ICS), over-reliance on short-acting beta-agonists (SABA) and poor inhaler technique. 

The module will also explore the role of pharmacists in improving outcomes via better self-management and enhanced adherence to the latest clinical guidance. 

Completing this module will help you adapt the information and advice you give on newly prescribed asthma treatments in services such as the NMS.

Key facts

• Asthma is a variable condition, usually with symptoms of wheeze, cough, chest tightness and shortness of breath
• New NICE/BTS/SIGN guidance on the diagnosis, monitoring and managment of chronic asthma recommends a SABA-free pathway to treatment 
• A combination inhaler of inhaled corticosteroid (ICS) and formoterol is now the mainstay of asthma treatment
• Combination inhalers are used as anti-inflammatory relievers (AIR) in mild asthma or maintenance and reliever therapy (MART) in patients experiencing daily symptoms or being woken by their asthma one night a week or more
• The new clinical guidance recommends greater use of blood tests and FeNO monitoring that measures fractional exhaled nitric oxide.

Contribution author: Darush Attar-Zadeh, respiratory pharmacist at NW London ICB. 

Additional contributions from Professor Alison Blenkinsopp.